Pharmacy

Your Article Summary

See Latest Articles

Insomnia-related comorbidities and economic costs among a commercially insured population in the United States
Current Medical Research and Opinion, 06/29/09

Pollack M et al. - Though identified patients were required to have enrollment in both medical and productivity databases, and the presence of insomnia could not be verified through medical records, these results suggest a significant link between insomnia and higher rates of comorbid conditions, healthcare expenditures and productivity losses. Payers and employers should consider insomnia as a factor in disease-related case-management initiatives.

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial
The Lancet, 10/13/09

Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09

See All of Neuro/Psych pharmacology

Today in Pharmacoeconomics...keeping you current

Receive free subspecialty "5-minute updates" via email

Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09

Use and cost of branded and generic drugs in patients with coronary heart disease-results from a prospective survey of 1008 patients in two London hospitals
QJM: An International Journal of Medicine, 10/16/09

Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting
Clinical Drug Investigation, 10/15/09

See All of Pharmacoeconomics